Quidelortho Corp (QDEL) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Quidelortho Corp (QDEL) stock forecast summary
Our AI scores Quidelortho Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Quidelortho Corp is a small-cap company with a market capitalization of $734M. It ranks number 6 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its D/E Ratio of 2.23x is the highest of the 12 peers that report one.
For QDEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 4.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 13.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, QDEL included.
QDEL price chart and AI forecast
How QDEL ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Quidelortho Corp (QDEL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | QDEL | Rank |
|---|---|---|
| Market Cap | $734M | 6/17 |
| P/B Ratio | 0.41x | 11/12 |
| EPS | $-6.79 | – |
| Book Value/Share | $26.12 | – |
| Revenue/Share | $46.85 | – |
| FCF/Share | $-4.70 | – |
Profitability & Margins
| Metric | QDEL | Rank |
|---|---|---|
| ROE | -20.6% | 5/10 |
| ROA | -6.4% | 5/12 |
| ROIC | -3.4% | 5/12 |
| Gross Margin | 55.0% | 4/9 |
| Operating Margin | -5.0% | 6/14 |
| Net Margin | -11.5% | 6/11 |
| EBT Margin | -12.9% | 6/14 |
| Tax Rate | -10.9% | – |
Financial Health
| Metric | QDEL | Rank |
|---|---|---|
| Current Ratio | 1.36x | 12/16 |
| Quick Ratio | 0.75x | 9/10 |
| D/E Ratio | 2.23x | 1/12 |
| Financial Leverage | 3.23x | 1/12 |
| Interest Coverage | -0.4x | 8/15 |
| Working Capital | $379M | 5/16 |
Cash Flow
| Metric | QDEL | Rank |
|---|---|---|
| Operating Cash Flow | -$253M | 15/16 |
| Free Cash Flow | -$322M | 9/10 |
| Capital Spending | -$69M | 9/10 |
| OCF Growth YoY | -214.7% | 5/5 |
| FCF Growth YoY | -769.1% | – |
| FCF/Sales | -10.0% | 5/10 |
| CapEx/Sales | 2.2% | 7/10 |
Operational Efficiency
| Metric | QDEL | Rank |
|---|---|---|
| Asset Turnover | 0.56x | 5/12 |
| Receivables Turnover | 8.6x | 3/11 |
| Inventory Turnover | 2.2x | 9/10 |
| Fixed Assets Turnover | 2.4x | 6/12 |
| Days Sales Outstanding | 43 days | 9/11 |
| Days Inventory | 162 days | 2/10 |
| Payables Period | 64 days | 4/10 |
| Cash Conversion Cycle | 141 days | 2/8 |
Income Statement
| Metric | QDEL | Rank |
|---|---|---|
| Total Revenue | $3.21B | 2/12 |
| Operating Income | -$159M | 13/15 |
| Net Income | -$369M | 11/12 |
| R&D Expense | $227M | 4/16 |
| SG&A Expense | $965M | 2/12 |
| Cost of Goods Sold | $1.45B | 2/10 |
Dividend & Shareholder Information
| Metric | QDEL | Rank |
|---|---|---|
| Shares Outstanding | 69M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.45B | 25.0% of assets |
| Cash & Short-term Investments | $166M | 2.9% of assets |
| Accounts Receivable | $376M | 6.5% of assets |
| Inventory | $643M | 11.1% of assets |
| Total Liabilities | $3.99B | 69.0% of assets |
| Short-term Debt | $814M | 14.1% of assets |
QDEL quarterly financials and insider trading
Quidelortho Corp (QDEL) industry peers
Companies classified under the same SEC industry code as Quidelortho Corp (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| QDEL Quidelortho Corp | $734M | |
| IDXX Idexx Laboratories Inc /De | $53.26B | |
| LNTH Lantheus Holdings, Inc. | $6.57B | |
| NEOG Neogen Corp | $2.57B | |
| CLDX Celldex Therapeutics, Inc. | $2.35B | |
| NTLA Intellia Therapeutics, Inc. | $1.59B | |
| ACHV Achieve Life Sciences, Inc. | $692M | |
| MYGN Myriad Genetics Inc | $566M | |
| TKNO Alpha Teknova, Inc. | $482M | |
| ICCC Immucell Corp /De/ | $90M | |
| IMDX Insight Molecular Diagnostics Inc. | $81M | |
| AWHL Aspira Women's Health Inc. | $9M | |
| BMRA Biomerica Inc | $7M | |
| CDIO Cardio Diagnostics Holdings, Inc. | $5M | |
| TRIB Trinity Biotech Plc | $5M | |
| QCLS Q/C Technologies, Inc. | $3M | |
| VNRX Volitionrx Ltd | $3M |
Where QDEL sits on the market map
Quidelortho Corp (QDEL) stock news
Loading...
Quidelortho Corp (QDEL) stock forecast FAQ
What is the Quidelortho Corp (QDEL) stock forecast?
Our AI scores Quidelortho Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Quidelortho Corp stock predictions?
For QDEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 4.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 13.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Quidelortho Corp forecasts updated?
Quidelortho Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Quidelortho Corp's industry peers?
17 issuers in our coverage, QDEL included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Achieve Life Sciences, Inc. (ACHV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.